Glutamine (DrugBank: Glutamine)
7 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 87 | 肺静脈閉塞症／肺毛細血管腫症 | 1 |
| 89 | リンパ脈管筋腫症 | 1 |
| 96 | クローン病 | 1 |
| 97 | 潰瘍性大腸炎 | 1 |
| 113 | 筋ジストロフィー | 3 |
| 245 | プロピオン酸血症 | 1 |
| 299 | 嚢胞性線維症 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00563498 (ClinicalTrials.gov) | July 2004 | 21/11/2007 | Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients | A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis. | Pulmonary Veno-Occlusive Disease;Hepatic Veno-Occlusive Disease;Mucositis | Drug: Glutamine | Hospital Authority, Hong Kong | The University of Hong Kong;Fresienius Kabi HK Ltd | Recruiting | 18 Years | N/A | Both | 40 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04388371 (ClinicalTrials.gov) | October 18, 2019 | 11/5/2020 | Glutamine PET Imaging in LAM | Glutamine PET Imaging in LAM | Lymphangioleiomyomatosis (LAM) | Drug: Glutamine | Vanderbilt University Medical Center | The LAM Foundation | Enrolling by invitation | 18 Years | N/A | Female | 5 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00838149 (ClinicalTrials.gov) | November 2005 | 5/2/2009 | Effect of Glutamine on Intestinal Permeability in Crohn's Disease | Effect of Glutamine Supplementation on the Structure and Function of the Mucosa of Small Intestine in Crohn's Disease: A Randomized Controlled Trial | Crohn's Disease | Dietary Supplement: Glutamine;Dietary Supplement: Whey protein | All India Institute of Medical Sciences, New Delhi | NULL | Completed | 15 Years | 60 Years | Both | 30 | Phase 1 | India |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03917095 (ClinicalTrials.gov) | May 15, 2019 | 12/4/2019 | The Safety and Efficacy of TET Enema in the Treatment of UC | Mesalazine and Compound Glutamin Enema for the Treatment of Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing: A Multicenter, Randomized, Controlled Trail | Ulcerative Colitis Chronic Mild;Ulcerative Colitis Chronic Moderate | Device: The Colonic Transendoscopic enteral Tubing.;Drug: Glutamine;Drug: Mesalazine | The Second Hospital of Nanjing Medical University | NULL | Recruiting | 18 Years | 65 Years | All | 75 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00296621 (ClinicalTrials.gov) | February 2006 | 23/2/2006 | Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy | Efficacy Study of Oral Glutamine Supplementation in Duchenne Muscular Dystrophy | Muscular Dystrophy, Duchenne | Drug: L-Glutamine;Drug: placebo | Assistance Publique - Hôpitaux de Paris | NULL | Completed | N/A | N/A | Male | 30 | Phase 2 | France |
| 2 | NCT00018109 (ClinicalTrials.gov) | June 2001 | 3/7/2001 | A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD) | A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD) | Muscular Dystrophy, Duchenne | Drug: glutamine;Drug: creatine monohydrate | National Center for Research Resources (NCRR) | Children's Research Institute | Completed | 5 Years | 10 Years | Male | Phase 3 | United States | |
| 3 | NCT00016653 (ClinicalTrials.gov) | June 2000 | 21/5/2001 | Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy | A Multicenter Randomized Placebo-controlled Double-blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy | Muscular Dystrophy, Duchenne | Drug: Creatine Monohydrate;Drug: Glutamine | Cooperative International Neuromuscular Research Group | NULL | Completed | 5 Years | 9 Years | Male | 48 | Phase 2;Phase 3 | United States;Belgium;Israel;Puerto Rico |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00645879 (ClinicalTrials.gov) | July 2008 | 25/3/2008 | Anaplerotic Therapy in Propionic Acidemia | Safety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia. | Propionic Acidemia | Drug: ornithine alpha ketoglutarate;Drug: glutamine;Drug: disodium citrate | Nicola Longo | National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 5 Years | 12 Years | Both | 3 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01051999 (ClinicalTrials.gov) | February 2010 | 15/1/2010 | Glutamine Supplementation in Cystic Fibrosis | Glutamine Supplementation and Immunity in Adults With Cystic Fibrosis | Cystic Fibrosis;Immune Function | Dietary Supplement: Glutamine;Dietary Supplement: L-alanine | Emory University | Emmaus Medical, Inc. | Completed | 18 Years | N/A | Both | 17 | Phase 2 | United States |
| 2 | EUCTR2007-006204-37-GB (EUCTR) | 03/07/2008 | 09/05/2008 | Glutamine supplementation for cystic fibrosis: a parallel group randomized controlled trial - Glutamine and CF | Glutamine supplementation for cystic fibrosis: a parallel group randomized controlled trial - Glutamine and CF | Cystic fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis | University of Nottingham | NULL | Not Recruiting | Female: yes Male: yes | 44 | Phase 4 | United Kingdom |